ERBB2 and breast cancer: Notable examples include the HER2CLIMB trial, which demonstrated the efficacy of tucatinib in HER2-positive breast cancer, and the ASCENT trial, showcasing the benefits of Sacituzumab govitecan in metastatic triple-negative breast cancer.77,117 Nevertheless, challenges, such as patient selection criteria, optimal dosing strategies, and the emergence of resistance mechanisms, remain subjects of ongoing research and refinement.118